2020
領先的慢(màn)病管理生态 The leading ecosystem of chronic disease management

打造醫、患、藥、保等一體化慢(màn)病管理及服務平台 Building a chronic disease management and service platform integrating hospital, patient, pharmacies and insurance

智雲健康慢(màn)病管理系統馳援火(huǒ)神山醫院 Cloudr Health Chronic Disease Management System assisted Huoshenshan Hospital

攜手新華社半月談,共同舉辦“後疫情時代‘互聯網+醫療健康’創新發展論壇” Join hands with the Xinhua News Agency-China Comment to jointly hold the "Internet + Medical and Health Innovation Development Forum in the Post-epidemic Era"

2018
爆發式成長 Explosive Growth

合作醫院近1000家,業務收入實現(xiàn)300%的增長 Close to 1,000 partner hospitals; 300% growth in revenues Team expanded with many talents from leaders in the medical and internet industries, such as Johnson & Johnson, Kanghong Pharmaceutical, and Alibaba, among others

吸引大批來自強生、康弘藥業、阿裏巴巴等醫療與互聯網頭部公司優秀人才加入

2016
醫院爲先,進軍醫院SaaS系統 Hospital first strategy
公司進行戰略轉型,啓動醫院SaaS業務,發力服務醫院與醫生啓動醫院SaaS業務 Pivot to a SaaS-based business model, hoping to serve hospitals and doctors more systematically
2014
公司創立 Founding
杭州康晟健康管理咨詢有限公司正式成立,希望通過先進互聯網技術改善醫患關系,提升醫療效率,幫助醫療資源合理分配

Hangzhou Kangsheng Health Management and Consulting Co., Ltd. founded.

Our mission: Leverage internet technologies to build stronger trust between doctors and patients, make healthcare more efficient and to improve the allocation of medical resources

2019
堅持自我造血,獲得市場認可 Continuing innovation and winning recognition

拓展慢(màn)病生态鏈,全面提升技術與服務品質 Expanding the eco-chain of chronic diseases management while upgrading technologies and improving service quality

繼醫院SaaS後,智雲新開發藥店SaaS系統與大數據平台 Developing our SaaS system for pharmacies and our database

2017
智雲健康 ClouDr

智雲銀川互聯網醫院成立,品牌全面升級爲“智雲健康” Branding upgraded to ClouDr; Yinchuan e-Clinic created.

服務範圍由糖尿病轉爲整個慢(màn)病領域,與近500家醫院達成合作 Our scope expanding from diabetes to all chronic diseases; partnering with nearly 500 hospitals

核心用戶超過500萬人 Core users exceeded 5 million

2015
掌上糖醫 APP for Diabetics
公司旗下第一款APP“掌上糖醫”問世,憑借有效與易用特性成爲廣受認可的在線(xiàn)醫療平台之一;11月,服務糖尿病患者突破100萬 Our first APP for diabetics launched, winning acclaim for its effectiveness and user-friendliness; by November, over 1 million diabetics were using the APP
發展曆程 Our Journey